CB-17 SCID mice (8 weeks old) received 5 daily i.p. injections of SNX2-1-165 (40 mg/kg) or carrier only, 10 mice per group. Mice were then injected s.c. with 1 x 106 cells of human A549 lung cancer cell line; the tumor cells were injected in the afternoon of the same day when the last dose of treatment was administered in the morning. Starting from day 7 after tumor injection, mice were monitored for tumor formation twice a week, with 3-4 day intervals, until day 24 after tumor injection; tumor volumes were calculated via caliper measurements.

MDA-MB-468 and MDA-MB-157 cells were plated in 96-well plates, at 1,500 cells/well, and exposed to carrier or increasing concentrations of SNX2-1-165 (SENEXIN B) for five days; cell survival was measured by the MTT assays. MDA-MB-468 and MDA-MB-157 displayed dose-dependent growth inhibition by SNX2-1-165.